Work

Isoform-selective activity-based profiling of ERK signaling

Year: 2018
Type: article
Abstract: ERK2 across a variety of cell types, tissues, and species. We used our chemoproteomic strategy to determine potency and selectivity of academic (VX-11e) and clinical (Ulixertinib) ERK inhibitors. Correlation of potency estimates by chemoproteomics with anti-proliferative activity of VX-11e and Ulixertinib revealed that >90% inactivation of both native ERK1 and ERK2 is needed to mediate cellular activity of inhibitors. Our findings introduce one of the first assays capable of independent evaluation of native ERK1 and ERK2 activity to advance drug discovery of oncogenic MAPK pathways.
Language: English
Open Access status: diamond
OpenAlex ID: W2787283083
FWCI: 1.743
Cites: 68
Cited by: 50
Related to: 10